Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the ...

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute ...

The FDA has granted fast track designation to HC-7366 for the treatment of adult patients with relapsed/refractory acute ...

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

Severe symptoms during pregnancy led to a leukemia diagnosis after collapsing at work. The patient underwent chemotherapy while pregnant and delivered her son at 32 weeks. She continued treatment post ...

HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...